Skip to Main Content

Robert J. Schneider

Associate Dean for Therapeutics Alliances

Albert B. Sabin Professor of Microbiology and Molecular Pathogenesis, Department of Microbiology

Professor, Department of Radiation Oncology

Keywords
cancer, developmental genetics, genome integrity, microbiology, pharmacology, RNA biology, stem cell biology
Summary

I am the Albert Sabin Professor of Molecular Pathogenesis, Associate Dean for NYU Technology Ventures and Partnerships (the technology, commercialization and therapeutics discovery office of NYU), and Co-director of the Breast Cancer Research Program at NYU School of Medicine. Our research is directed to three major areas: (1) translational regulation of advanced breast cancers and the development of new treatment strategies and therapeutics for advanced cancers; (2) translational regulation of the immune response and applications in development of immune-oncology therapeutics; (3) and regulation of adult tissue stem cells and tissue regeneration controlled by targeted mRNA decay and translational regulation.

Phone

212-263-6006

Academic office

450 East 29th Street

3rd floor

New York, NY 10016

Lab Website
Schneider Lab
Is this your profile?
Edit profile

These focus areas and their associated publications are derived from medical subject headings from PubMed.
represents one publication
Loading...

Positions

Albert B. Sabin Professor of Microbiology and Molecular Pathogenesis, Department of Microbiology

Professor, Department of Radiation Oncology

Associate Dean for Therapeutics Alliances

Residency And Fellowship Training

Fellowship, SUNY Stony Brook/Princeton University, Virology-Virus-cell Interactions

Inflammatory Breast Cancer Promotes Development of M2 Tumor-associated Macrophages and Cancer Mesenchymal Cells Through a Complex Cytokine Network

Valeta-Magara, Amanda; Gadi, Abhilash; Volta, Viviana; Walters, Beth; Arju, Rezina; Giashuddin, Shah; Zhong, Hua; Schneider, Robert J

Cancer research. 2019 May 01;

Molecular basis for AU-rich element recognition and dimerization by the HuR C-terminal RRM

Ripin, Nina; Boudet, Julien; Duszczyk, Malgorzata M; Hinniger, Alexandra; Faller, Michael; Krepl, Miroslav; Gadi, Abhilash; Schneider, Robert J; Šponer, Jiří; Meisner-Kober, Nicole C; Allain, Frédéric H-T

Proceedings of the National Academy of Sciences of the United States of America (PNAS). 2019 Feb 19; 116(8):2935-2944

Differential Regulation of the Three Eukaryotic mRNA Translation Initiation Factor (eIF) 4Gs by the Proteasome

Alard, Amandine; Marboeuf, Catherine; Fabre, Bertrand; Jean, Christine; Martineau, Yvan; Lopez, Frédéric; Vende, Patrice; Poncet, Didier; Schneider, Robert J; Bousquet, Corinne; Pyronnet, Stéphane

Frontiers in genetics. 2019 Feb; 10:254

<i>Ganoderma lucidum</i> extract (GLE) impairs breast cancer stem cells by targeting the STAT3 pathway

Rios-Fuller, Tiffany J; Ortiz-Soto, Gabriela; Lacourt-Ventura, Mercedes; Maldonado-Martinez, Gerónimo; Cubano, Luis A; Schneider, Robert J; Martinez-Montemayor, Michelle M

Oncotarget. 2018 Nov 13; 9(89):35907-35921

RIVET: comprehensive graphic user interface for analysis and exploration of genome-wide translatomics data

Ernlund, Amanda W; Schneider, Robert J; Ruggles, Kelly V

BMC genomics. 2018 Nov 08; 19(1):809

mTORC1/2 inhibition re-sensitizes platinum-resistant ovarian cancer by disrupting selective translation of DNA damage and survival mRNAs

David-West, Gizelka; Ernlund, Amanda; Gadi, Abhilash; Schneider, Robert J

Oncotarget. 2018 Sep 04; 9(69):33064-33076

A widespread alternate form of cap-dependent mRNA translation initiation

de la Parra, Columba; Ernlund, Amanda; Alard, Amandine; Ruggles, Kelly; Ueberheide, Beatrix; Schneider, Robert J

Nature communications. 2018 08 03; 9(1):3068

Translational Control in Cancer

Robichaud, Nathaniel; Sonenberg, Nahum; Ruggero, Davide; Schneider, Robert J

Cold Spring Harbor perspectives in biology. 2018 Jun 29;

See All Publications (149)

Read Story
Read Story
Read Story